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OBJECTIVEdA 12-week study assessed the efﬁcacy and safety of a new oral antidiabetic
agent, imeglimin, as add-on therapy in type 2 diabetes patients inadequately controlled with
metformin alone.
RESEARCHDESIGNANDMETHODSdA total of 156 patients were randomized 1:1 to
receive imeglimin (1,500mg twice a day) or placebo added to a stable dose of metformin (1,500–
2,000 mg/day). Change in A1C from baseline was the primary efﬁcacy outcome; secondary
outcomes included fasting plasma glucose (FPG) and proinsulin/insulin ratio.
RESULTSdAfter 12 weeks, the placebo-subtracted decrease in A1C with metformin-imeglimin
was 20.44% (P , 0.001). Metformin-imeglimin also signiﬁcantly improved FPG and the
proinsulin/insulin ratio from baseline (20.91 mg/dL and 27.5, respectively) compared with
metformin-placebo (0.36 mg/dL and 11.81). Metformin-imeglimin therapy was generally well-
tolerated with a comparable safety proﬁle to metformin-placebo.
CONCLUSIONSdAddition of imeglimin to metformin improved glycemic control and
offers potential as a new treatment for type 2 diabetes.
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Imeglimin is the ﬁrst in a new tetrahy-drotriazine-containing class of oralantidiabetic agents, the glimins. Ime-
glimin decreases hepatic glucose produc-
tion, increases muscle glucose uptake, and
improves pancreatic glucose-dependent
insulin secretion (1).
Previous studies have demonstrated
imeglimin to be as effective as metformin
in improving glycemia (2). Since metfor-
min is the preferred ﬁrst-line therapy for
type 2 diabetes, the current study exam-
ined the efﬁcacy, safety, and tolerability of
imeglimin in combination with metfor-
min in patients with type 2 diabetes
inadequately controlled with metformin
alone.
RESEARCH DESIGN AND
METHODSdThis was a 12-week,
multicenter (20 centers in three coun-
tries), randomized, double-blind, pla-
cebo-controlled, parallel-group study in
subjects with type 2 diabetes inadequately
controlled with the maximum tolerated
dose of metformin. The average metfor-
min doses at baseline remained the same
throughout the study: 1,901 mg in the
metformin-imeglimin group and 1,914
mg in the metformin-placebo group.
After screening, eligible subjects were
enrolled into a single-blind, placebo,
2-week run-in period under previous met-
formin treatment and placebo-imeglimin
twice a day (BID). Subjects were then
randomized 1:1 to receive 1,500 mg BID
imeglimin or placebo-imeglimin BID in
addition to their lead-in dose of metfor-
min for 12 weeks, followed by a 1-week
period with placebo-imeglimin.
Male and female subjects with type 2
diabetes (N = 156), aged $18 to #70
years, inadequately controlled (A1C $7.5%)
by metformin alone (1,500–2,000
mg/day, both inclusive) were included.
Enrolled subjects had received a stable
dose of metformin for at least 10 weeks
before randomization and had received no
other glucose-lowering medication within
3 months prior to randomization. Most
other therapeutic classes of concomitant
medication were permitted. Exclusion cri-
teria included impaired hepatic or renal
function, inadequately controlled hyper-
tension, and clinically signiﬁcant micro-
vascular or macrovascular complications.
The study protocol was approved by
the institutional review board and con-
ducted in accordance with the Declara-
tion of Helsinki and Good Clinical
Practice guidelines (3). All participants
provided written informed consent be-
fore any study-related activities.
The primary efﬁcacy outcome was
change in A1C from baseline to week 12.
Secondary end points included changes
from baseline in fasting plasma glucose
(FPG; mg/dL) and proinsulin (pmol/L)/
insulin (mIU/mL) ratio. The percentage of
patients achieving an A1C ,7% or a de-
crease from baseline $0.5% at week 12
were calculated, and subgroup analyses
were performed to determine the effect
of baseline A1C and BMI on the change
in A1C from baseline to week 12.
Adverse events were speciﬁcally as-
sessed into treatment-related and severity.
Statistical analysis
Intention-to-treat efﬁcacy analysis included
all randomized subjects who received
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at least one dose of imeglimin or placebo
and provided a baseline and at least one
postbaseline A1C value. Data are presented
as last observation carried forward (LOCF).
Change of A1C frombaseline toweek 12 or
LOCF was assessed with an ANCOVA
model. Statistical signiﬁcance was assessed
at the 5% level.
RESULTSdDemographic and baseline
characteristics were similar between the
two treatment arms. A1C decreased from
baseline to week 12 by 20.65% with
metformin-imeglimin and 20.21% with
metformin-placebo groups (P = 0.001),
resulting in a mean treatment difference
of 20.44% (95% CI 20.71 to 20.17).
Statistically signiﬁcant reductions in FPG
(P , 0.001) and the proinsulin/insulin
ratio (P = 0.007) from baseline compared
with metformin-placebo were also ob-
served (Table 1).
More subjects achieved a decrease in
A1C $0.5% with metformin-imeglimin
(63.6%) than metformin-placebo (36.4%)
Table 1dEfﬁcacy and safety results of the imeglimin add-on to metformin phase II study
Statistic/category Characteristic Metformin + imeglimin 1,500 mg BID Metformin + placebo
Baseline A1C (%)
N 77 78
Mean (SD) 8.5 (0.72) 8.6 (0.73)
Minimum–maximum 7.1–10.2 7.3–10.2
Week 12 (end of treatment)
N 68 69
Mean (SD) 7.84 (1.03) 8.31 (0.94)
Minimum–maximum 5.5–11.0 6.6–11.3
Change from baseline to week 12 (LOCF)
LS mean (SE) 20.65 (0.1) 20.21 (0.1)
P value compared with placebo P = 0.001
Baseline FPG (mg/dL)
N 77 78
Mean (SD) 10.4 (2.47) 10.28 (2.32)
Minimum–maximum 6.4–18.9 6.4–17.1
Week 12 (end of treatment)
N 67 71
Mean (SD) 9.53 (2.57) 10.59 (2.62)
Minimum–maximum 5.5–18.5 4.0–18.7
Change from baseline to week 12 (LOCF)
LS mean (SE) 20.91 (0.24) 0.36 (0.24)
P value compared with placebo P , 0.001
Baseline Proinsulin/insulin ratio
N 61 64
Mean (SD) 64.12 (36.18) 62.62 (37.03)
Minimum–maximum 2.3–168.7 9.6–211.9
Week 12 (end of treatment)
N 53 56
Mean (SD) 58.15 (29.54) 74.32 (52.03)
Minimum–maximum 10.5–176.5 19.7–288.3
Change from baseline to week 12 (LOCF)
LS mean (SE) 27.5 (5.12) 11.81 (4.83)
P value compared with placebo P = 0.007
Any TEAE Adverse events
Number of events 43 28
Number of subjects with AEs (%) 18 (23.1) 15 (19.2)
SAE
Number of events 0 3
Number of subjects with AEs (%) 0 (0.0) 3 (3.8)
TEAE leading to withdrawal
Number of events 2 1
Number of subjects with AEs (%) 2 (2.6) 1 (1.3)
EAC adjudicated CV event
Number of events 0 4
Number of subjects with AEs (%) 0 (0.0) 2 (2.6)
AE, adverse events; CV, cardiovascular; EAC, Event Adjudication Committee;N = number of subjects exposed; SAE, serious adverse event; TEAE, treatment-emergent
adverse event.
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(P = 0.001). Furthermore, 14.3% of sub-
jects receiving metformin-imeglimin
achieved an A1C ,7% compared with
3.8% of subjects receiving metformin-
placebo (P = 0.04).
Metformin-imeglimin was more ef-
fective than placebo in reducing mean
A1C from baseline after 12 weeks of
treatment in all subgroup analyses. For
prespeciﬁed baseline A1C subgroup
measurements ,8.0%, 8.0–9.0%, and
.9.0%, reductions in mean (SD) A1C (%)
from baseline to week 12 for metformin-
imeglimin were 20.41% (0.44), 20.68%
(0.86), and 20.78% (0.98), respectively,
as compared with 20.09% (0.59),
20.15% (0.96), and 20.43% (0.89) for
metformin-placebo. Reductions in A1C
based on baseline BMI were similar for
subjects with baseline BMI (kg/m2) #30
kg/m2 and for subjects with baseline BMI
(kg/m2) .30 kg/m2 for both treatment
arms of the study.
Metformin-imeglimin therapy was
well-tolerated with a safety proﬁle com-
parable to metformin-placebo. No serious
adverse events or cardiovascular events
were reported with metformin-imeglimin.
Although not statistically signiﬁcant, a
slight decrease in mean values for body
weight (P = 0.08) and waist circumference
(P = 0.053) was observed for metformin-
imeglimin compared with metformin-
placebo.
CONCLUSIONSdCurrent guidelines
recommend metformin as the ﬁrst-line
pharmacological treatment for type 2 di-
abetes (4). However, metformin alone is
frequently insufﬁcient to obtain or main-
tain glycemic goals; therefore, many
patients require multiple pharmacothera-
pies for optimal disease management (5).
The current study shows that imeglimin
appeared to complement the actions of
metformin by producing modest, but
clinically and statistically signiﬁcant im-
provements in A1C, FPG, and proinsulin/
insulin ratio. Metformin-imeglimin pro-
gressively reduced the mean A1C value
throughout the 12-week treatment pe-
riod, implying that further improvements
might be expected beyond 12 weeks. This
reduction in A1C is comparable to other
recently approved antihyperglycemic
treatments (6–8). Furthermore, the effect
on A1C is related to beneﬁcial effects of
imeglimin on both FPG and glucose toler-
ance, as previously demonstrated (9).
Metformin-imeglimin was effective in
reducing the proinsulin/insulin ratio,
indicating a potential beneﬁcial effect of
imeglimin on b-cell function. Further
studies are necessary to determine if this
translates to b-cell protection over time,
as suggested in previous preclinical studies
in which imeglimin reduced b-cell ap-
optosis induced by cytokine stress and
high glucose conditions (2).
Drug–drug interaction studies in
healthy subjects have shown thatmultiple
dosing of imeglimin did not affect met-
formin exposure (unpublished data,
Poxel). The novel mechanism of action
of imeglimin provides additional beneﬁts
to metformin monotherapy in patients
with type 2 diabetes.
Metformin-imeglimin was generally
well-tolerated compared with metformin-
placebo with no serious adverse events or
cardiovascular events reported. This
phase II study demonstrated that ﬁrst-
in-class imeglimin was well-tolerated and
effective when combined with metformin
as a potential new treatment for type 2
diabetes.
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